Received May 21, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Shingrix dose two given less than two months after dose one; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 67-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Concomitant products included Varicella zoster vaccine rgE (CHO) (Shingrix). On 17-APR-2026, the patient received the 2nd dose of Shingrix. On 17-APR-2026, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: Shingrix dose two given less than two months after dose one). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 14-MAY-2026 The pharmacist confirmed that the patient was not immunodeficient or immunosuppressed, the dose two was administered less than two months after dose one. The batch number was not provided upon follow- up with the reporter.
Shingrix